Lund, Sweden, February 26, 2021 - BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per February 26, 2021 amounts to 42,210,495 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 143 to Swedish and international institutional investors by issuance of 2,834,399 shares, announced on February 23, 2021.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Senior Director Investor Relations
+46 (0)46 286 85 50
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00 am CET on February 26, 2021.